. – Public Listing offers Access to CAD 52 Million from Share Subscription and Drawdown Agreement, Sufficient Funding to Complete Development and Launch Avisa BreathTest™ – Pivotal Trials Planned in Post-COVID-19 Long Haulers and Ventilator-Associated Pneumonia Avisa Diagnostics Inc. (Avisa) is pleased to announce that the Company has begun trading […]
22. Dezember 2024
